



## Active substances set

**Search phrase:** sugemalimab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

### Tracheal, bronchus, and lung cancer

#### Sugemalimab

Sugemalimab in combination with platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations.



**NO REIMBURSEMENT**



**ESMO**